HWL ‐088, a new and highly effective FFA1/PPARδ dual agonist, attenuates nonalcoholic steatohepatitis by regulating lipid metabolism, inflammation and fibrosis

ConclusionsThese positive results indicated that PPAR δ/FFA1 dual agonist HWL‐088 might be a potential candidate to improve multiple pathogenesis of NASH.

Source: Journal of Pharmacy and Pharmacology - July 30, 2020 Category: Drugs & Pharmacology Authors: Lijun Hu, Zongtao Zhou, Liming Deng, Qiang Ren, Zongyu Cai, Bin Wang, Zheng Li, Guangji Wang Tags: Research Paper Source Type: research